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Abstract
Background: The etiology of Kawasaki Disease (KD) is enigmatic, although an infectious cause is suspected. Polymorphisms
in CC chemokine receptor 5 (CCR5) and/or its potent ligand CCL3L1 influence KD susceptibility in US, European and Korean
populations. However, the influence of these variations on KD susceptibility, coronary artery lesions (CAL) and response to
intravenous immunoglobulin (IVIG) in Japanese children, who have the highest incidence of KD, is unknown.
Methodology/Principal Findings: We used unconditional logistic regression analyses to determine the associations of the
copy number of the CCL3L1 gene-containing duplication and CCR2-CCR5 haplotypes in 133 Japanese KD cases [33 with CAL
and 25 with resistance to IVIG] and 312 Japanese controls without a history of KD. We observed that the deviation from the
population average of four CCL3L1 copies (i.e., , or . four copies) was associated with an increased risk of KD and IVIG
resistance (adjusted odds ratio (OR) =2.25, p=0.004 and OR=6.26, p=0.089, respectively). Heterozygosity for the CCR5
HHF*2 haplotype was associated with a reduced risk of both IVIG resistance (OR=0.21, p=0.026) and CAL development
(OR=0.44, p=0.071).
Conclusions/Significance: The CCL3L1-CCR5 axis may play an important role in KD pathogenesis. In addition to clinical and
laboratory parameters, genetic markers may also predict risk of CAL and resistance to IVIG.
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Introduction
Kawasaki disease (KD) is an acute, self-limiting systemic
vasculitis of infants and children [1,2]. The most serious
complication of KD is the development of coronary artery lesions
(CAL) that range from transient dilatation to destruction of the
vessel wall architecture resulting in aneurysms [3]. Indeed, the
primary goal of KD treatment is to prevent this complication
[1,2]. There is significant inter-individual variation in KD
susceptibility as well as CAL development. Moreover, although
administration of a combination of a high dose intravenous
immunoglobulin (IVIG) and aspirin is the standard therapy for
acute KD, 15–30% of KD patients have persistent or recurrent
fever after IVIG treatment [4,5,6,7,8,9,10]. Also, such patients are
at increased risk of developing CAL [11]. Thus, identification of
host factors that influence KD susceptibility, CAL development
and resistance to IVIG treatment may provide new insights into
KD pathogenesis, novel means for prognostication of clinical
outcome, and therapeutic targets.
According to a current paradigm, KD is thought to be triggered
by an infectious agent that elicits an inflammatory response
directed at cardiovascular tissues in genetically susceptible hosts
[1,12,13]. Polymorphisms in various genes have been shown to
influence KD susceptibility in different populations [14,15,16,17,
18,19,20,21,22]. Similarly, variations in the genes encoding CD14
[23], matrix metalloproteinase (MMP)-3 [24], vascular endothelial
growth factor (VEGF) and its receptor kinase insert domain
receptor (KDR) [21] have been implicated in CAL development in
KD. With respect to response to IVIG, several studies have
reported laboratory and demographic predictors associated with
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systems based on such predictors to multiethnic U.S. populations
has not been successful [10]. The genetic basis of IVIG resistance
in the setting of KD or other inflammatory, autoimmune and
infectious diseases in which IVIG has been empirically used (e.g.
Idiopathic thrombocytopenic purpura), including pediatric HIV
and post-infectious complications [25], has not been fully
elucidated.
There is evidence to suggest that recruitment of inflammatory
cells in KD may be mediated through CC chemokine receptor 5
(CCR5) [15,19,26]. Chemotactic gradients for homing of CCR5+
cells are provided by a variety of chemokines, the most potent of
which is its ligand - CC ligand 3 like 1 (CCL3L1) [27]. The genes
encoding CCR5 and CCL3L1 demonstrate two distinct types of
polymorphisms: single nucleotide polymorphisms in CCR5 [28]
and copy number variation (CNV) in the CCL3L1-gene containing
segmental duplication [29]. There is a growing interest in
understanding the contribution of CNV in disease pathogenesis
since it is recognized that 12% of the human genome may have
undergone segmental duplications [30,31]. We previously found
that variations in CCR5 and CCL3L1 affect susceptibility to KD in
parent-child trios from the United States [15].
However, there is significant variation in the prevalence of KD
as well as the frequency of CCR5 genotypes and CCL3L1 copy
number in different populations [15,27,32]. Consequently,
whether the observations made in US trios can be generalized
to Japanese children is unknown. To address this, we conducted a
case-control study in subjects from Japan, a geographic region
where the prevalence of KD is at least 10 times higher than the
Western world [1,2]. We tested the hypothesis that CCR5
haplotypes and CCL3L1 copy number influence KD susceptibility
and two disease-related outcomes: development of CAL and IVIG
resistance.
Materials and Methods
Ethics Statement
This study was approved by the institutional review boards of
Yamaguchi and Kurume University Hospitals in Japan and the
University of California San Diego and the University of Texas
Health Science Center in San Antonio in the U.S. and written
informed consent was given by the parents of all KD subjects and
controls.
Study subjects
We conducted an unmatched case-control study of 133 cases of
KD and 312 controls collected between January 2002 and April
2005. The KD patients were recruited from three sites: the
Department of Pediatrics, Yamaguchi University Hospital; Oita
Children’s Hospital; and Kurume University Hospitals, Japan. All
patients met the Japanese criteria for the diagnosis of KD [33].
CAL was defined as a luminal diameter .3 mm for patients ,4
years or .4 mm for patients .5 years of age, or an internal
diameter of one or more segments at least 1.5 times larger than the
adjacent segment [34]. IVIG-resistant subjects were defined as KD
patients who had persistent fever ($38.0uC) for at least 36 hours
after completion of the IVIG infusion and who received secondary
treatment after the initial treatment with IVIG. KD patients who
did not receive secondary treatment were considered to have
responded to the initial IVIG treatment. The initial IVIG was
administered as a single infusion of 2 g/kg/day. All KD patients
also received oral aspirin (30 mg/kg/d). Controls were Japanese
adults without a history of KD recruited from three centers: San
Diego, CA, and Yamaguchi University and RIKEN in Tokyo,
Japan. Most of the controls of Japanese origin (28% from
Yamaguchi University, 60% from Riken, and 12% from San
Diego) were healthy adults and some had common diseases of
adulthood unrelated to KD.
Genotyping
The methods for genotyping CCR5 polymorphisms are
described elsewhere [15,27,32]. The variations in CCR5 were
categorized into haplotypes as described previously and were
designated as CCR5 human haplogroups A (HHA), HHB, HHC,
HHD, HHE, HHF*1, HHF*2, HHG*1, and HHG*2 [35]. The
CCR5 haplotypes that bear the CCR5-D32 or CCR2-64I polymor-
phisms are designated as the CCR5 HHG*2 and HHF*2
haplotypes, respectively [32,35] Copy number of the CCL3L1
gene-containing segmental duplication was estimated as described
previously [27]. The assay used to genotype CCL3L1 copy number
captures three separate CCL3L genes (CCL3L1, CCL3L2 and
CCL3L3) as described previously [27].
Statistical analysis
Allele frequency and Hardy-Weinberg equilibrium for all the
CCR5 haplotypes was estimated using the PowerMarker software
[36]. We used unconditional multiple logistic regression analysis to
evaluate the association of CCR5 haplotypes and CCL3L1 copy
number with KD-related outcomes. The median number of
CCL3L1 copies in the study population was 4 and for this reason
the study subjects were trichotomized into those possessing ,4, 4
and .4 CCL3L1 copies. In these regression analyses, we included
CCR5 haplotypes (HHA, HHC, HHE, HHF*1, HHF*2 and
HHG1) and CCL3L1 copy number (less than 4 and greater than 4)
in the same regression model. To determine whether CCL3L1 gene
copy number modified the KD-influencing effects of CCR5
haplotypes, we used the Mantel-Haenszel test of homogeneity.
We used Stata 10.0 (Stata Corp, College Station, Texas) for the
statistical analysis.
Results
Among the cases there were 55 (41.35%) females and 78
(58.65%) males whereas in the control group there were 190
(60.90%) females and 122 (39.10%) males. KD patients with
available echocardiographic data were categorized into 2 groups
according to the presence of CAL. There were 33 (27.5%) and 87
(72.5%) patients with and without CAL, respectively. Mean age of
disease onset was 43.5 months (range 2–270 months). Of the 95
cases who were treated with IVIG within the first 10 days of onset
of fever, 25 (26.32%) were resistant to treatment.
The most common CCR5 haplotype was CCR5 HHC, followed
by HHF*2 and HHE (Fig. 1A). In the Japanese population the
HHG*2 haplotype bearing the CCR5-D32 mutation is very rare.
The CCR5 locus was in Hardy-Weinberg equilibrium (Exact
P=0.9808 in controls and 0.5624 in cases). The median CCL3L1
copy number in both cases and controls was four (Fig. 1B).
To determine whether CCR5 haplotypes or copy number of the
CCL3L1 gene-containing segemental duplication was associated
with an altered risk of developing KD, we first performed stepwise
unconditional logistic regression analyses. We found that both
possession of ,4 (OR=2.73, 95% CI=1.49–5.03, p=0.001) and
.4 CCL3L1 copies (OR=1.91, 95% CI=1.06–3.41, p=0.03) was
associated with an increased risk of developing KD (Table 1, Final
model).Sincegender distributionin the case and controlgroups was
different, we adjusted for this covariate, and the adjusted odds ratios
indicated that possession of ,4 (ORadjusted=2.64, 95% CI=1.42–
4.88, p=0.002) and .4 CCL3L1 copies (ORadjusted=2.00, 95%
CCR2-CCR5-CCL3L1 and KD
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higher risk of developing KD. Thus, departure from the population
average of 4 CCL3L1 copies (i.e., either , or .4 copies) was
associated with a significantly increased risk of KD before
(OR=2.21, 95% CI=1.28–3.82, p=0.004) and after adjustment
for gender (ORadjusted=2.25, 95% CI=1.29–3.91, p=0.004).
The results in Table 1 indicated that none of the CCR5
haplotypes had a significant association with the risk of KD. In
previous studies, we found that the copy number of CCL3L1
modified the SLE-, Kawasaki disease-, and HIV-1-disease-
influencing effects of CCR5 haplotypes ([15,37] and data not
shown). Thus, one possibility was that the association of CCR5
haplotypes with KD susceptibility is present only when it is present
in the context of a specific CCL3L1 copy number. To assess this
possibility, we conducted the analysis shown in Table 2. We found
that CCR5 haplotypes did not influence KD susceptibility in
subjects possessing ,4, .4 or 4 copies of CCL3L1 (Table 2).
In our cohort, of the 25 subjects who were resistant to IVIG, 18
(72%) developed CAL. By contrast, of the 68 who responded to
IVIG treatment, only 5 (7.3%) developed CAL. This association
between IVIG resistance and CAL development was highly
significant (Fisher’s exact p=1.4610
29). Evaluation of the
Figure 1. Distribution of CCR5 haplotypes and CCL3L1 copy number in cases (blue bars) and controls (purple bars). (A) Distribution of
CCR5 haplotypes and (B) Distribution of CCL3L1 copy number. The overall difference of distribution between cases and controls was tested for
significance using the x
2 test. The table at the bottom of Panel B shows frequencies of CCL3L1 copy number categories in cases and controls. The
categories were derived since 4 was the median copy number in the study population.
doi:10.1371/journal.pone.0011458.g001
CCR2-CCR5-CCL3L1 and KD
PLoS ONE | www.plosone.org 3 July 2010 | Volume 5 | Issue 7 | e11458association for the outcome of CAL revealed that possession of the
CCR2-64I-bearing CCR5 HHF*2 haplotype was associated with a
reduced risk of developing CAL which trended towards statistical
significance (OR=0.44, 95% CI=0.18–1.07, p=0.071). Howev-
er, we did not observe a significant association between CCL3L1
copy number and the risk of developing CAL.
We next determined whether CCR5 haplotypes and CCL3L1
copy number associated with IVIG responses. In the full model
(Table 3), possession of CCR5 HHF*2 haplotype was associated
with beneficial IVIG responses (OR=0.21, 95% CI =0.54–0.83,
p=0.026). We also found that possession of ,4 CCL3L1 copies
was significantly associated with an increased risk of IVIG
resistance (OR=10.93, 95% CI=1.17–101.99, p=0.036).
Although possession of .4 CCL3L1 copies was also associated
with an increased risk of IVIG resistance (OR=5.12, 95% CI =
0.57–46.34, p=0.146) (Table 3, Full Model), this did not achieve
statistical significance. In the final model (Table 3), possession of
,4 CCL3L1 copies remained associated with an increased risk of
IVIG resistance (OR=2.56, 95% CI =0.96–6.87, p=0.061)
while possession of CCR5 HHF*2 haplotype was associated
with a salutary IVIG response (OR=0.34, 95% CI =0.12–
0.95, p=0.040). Departure from the population average of 4
copies (i. e, , or .4 copies) was associated with a higher risk of
IVIG resistance (OR=6.26, 95% CI 0.76–51.9, p=0.089).
Because we observed that the CCR5 HHF*2 haplotype was
associated with a reduced risk of IVIG resistance as well as
development of CAL, we next examined whether these associa-
tions were due to homozygosity and/or heterozygosity of the
HHF*2 haplotype. We observed that heterozygosity but not
homozygosity for HHF*2 was associated with a reduced risk of
both CAL (OR=0.37, 95% CI 0.14–0.97, p=0.042) and IVIG
resistance (OR=0.39, 95% CI 0.14–1.11, p=0.078).
Discussion
Our results suggest that in Japanese children, copy number
variation of the segmental duplication bearing CCL3L1 associates
with susceptibility to KD and IVIG response whereas the CCR2-
64I-containing CCR5-HHF*2 haplotype is associated with a
reduced risk of both CAL development and IVIG resistance.
Our finding that deviation from the average CCL3L1 copy number
(i.e., , or .4 copies) found in the Japanese population is
associated with increased risk of KD is noteworthy because we
have previously found that deviation from median copy number of
CCL3L1 is also associated with an increased risk of systemic lupus
erythematosus (SLE) [37] – a disease with broad immunological
underpinnings – in three separate cohorts (TX, USA; Ohio, USA;
and Medellin, Colombia). The notion that haploinsufficiency and
higher gene dosages of immune response genes may influence
susceptibility to immune-mediated diseases is also highlighted by
our recent observation that both low and high copy numbers of
the gene encoding FCGR3B was associated with increased
susceptibility to SLE and primary Sjogren’s syndrome [38].
Together these observations underscore the concept that depar-
ture of the gene copy number from a homeostatic copy number,
i.e., higher or lower than the average found in the population, may
be an important determinant of susceptibility to diseases with a
strong immunologic component.
The precise mechanistic basis by which deviation from the
average copy number of the CCL3L1-containing segmental
duplication in our study population was associated with increased
KD susceptibility as well as an increased risk of IVIG failure is
unknown. As noted, CCL3L1 is the most potent CCR5 ligand and
CCR5 ligands are associated with pro-inflammatory effects [39].
Additionally, a copy number of the CCL3L1-containing segmental
duplication that is higher than the population average is associated
with increased leukocyte chemoattraction [29], circulating levels of
CCL3 [27] and CCL3L1 transcript (data not shown). In this light,
Table 1. Association of CCR5 haplotypes and CCL3L1 copy
number with Kawasaki disease susceptibility.
CCR5 haplotype/CCL3L1
copy number OR 95% CI P value
Full Model
CCR5 HHA 1.13 0.44–2.87 0.802
CCR5 HHC 0.70 0.39–1.26 0.236
CCR5 HHE 0.80 0.47–1.36 0.407
CCR5 HHF*1 0.58 0.12–2.91 0.512
CCR5 HHF*2 0.75 0.44–1.27 0.283
CCL3L1 ,4copies 2.71 1.47–4.99 0.001
CCL3L1 .4 copies 1.90 1.06–3.42 0.031
Final Model (Probability
Criterion of 0.1)
CCL3L1 ,4copies 2.73 1.49–5.03 0.001
CCL3L1 .4 copies 1.91 1.06–3.41 0.030
Full model shows results from a logistic regression model including all the
indicated predictors while final model indicates the results from the stepwise
regression using a retention criterion of 0.1; OR, Odds Ratio; CI, Confidence
Interval.
doi:10.1371/journal.pone.0011458.t001
Table 2. Lack of a modifying influence of the CCL3L1 gene copy number on the association of five common CCR5 haplotypes
found in the study population with the risk of KD.
CCR5 haplotype ,4 CCL3L1 copies 4 CCL3L1 copies .4 CCL3L1 copies M-H Test
OR 95% CI OR 95% CI OR 95% CI x
2 P
HHA 0.41 0.01–4.34 5.06 0.34–72.7 1.38 0.35–4.87 2.75 0.2531
HHC 1.22 0.54–2.81 0.93 0.30–3.10 0.65 0.32–1.33 1.54 0.4627
HHE 0.86 0.39–1.86 1.24 0.40–3.78 0.98 0.50–1.89 0.35 0.8398
HHF*1 --- --- 0.00 0.00–6.08 0.48 0.01–4.42 3.08 0.2139
HHF*2 0.92 0.42–1.98 0.66 0.21–2.02 0.98 0.50–1.91 0.43 0.8064
The last column shows the results of Mantel-Haenszel test for homogeneity of results across CCL3L1 copy number.
doi:10.1371/journal.pone.0011458.t002
CCR2-CCR5-CCL3L1 and KD
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segmental duplications may express higher levels of chemokines
following antigenic stimulus that in turn may increase the risk of
developing KD and possibly, IVIG resistance. In addition to
causing an immunologic blockade of Fc receptor and inducing
further antibody production, IVIG therapy is also known to play
an important role in down-regulation of the cytokine/chemokine
levels [40]. Conceptually then, in persons possessing high CCL3L1
gene copy numbers the currently used dose of IVIG may be
insufficient to induce the desired degree of down-regulation of
chemokines leading to IVIG resistance. The latter along with
increased CCL3L1 associated inflammation may provide a partial
explanation as to why we observed a trend for possession of a high
CCL3L1 copy number and reduced clinical responsiveness to
IVIG.
On the other hand, a low CCL3L1 copy number is associated
with reduced CCL3-CCL3L1 chemokine expression levels [29]
resulting in reduced inflammatory responses. It has been shown
that there is a surge in levels of several cytokines/chemokines
during the acute phase of KD [40,41,42,43,44] and we have
observed that the CCL3 surge is a key feature of the acute phase of
KD (data not shown). Thus, it is possible that an impaired CCL3-
CCL3L1-dependent inflammatory response may partly explain
increased risk of KD and reduced clearance of antigen.
Consequently, the increased and decreased inflammation associ-
ated with a high and low CCL3L1-containing segmental
duplication, respectively, may explain why all subjects do not
respond to a single dose of IVIG and require additional
treatments. This hypothesis is supported by the fact that greater
than half of IVIG-resistant patients who receive an additional dose
of IVIG become afebrile [10]. While appealing, laboratory or
clinical data that directly evaluates these hypotheses regarding
mechanisms by which a high or low CCL3L1 gene copy associates
with KD and IVIG non-responsiveness are currently lacking and
require validation.
The role of CCR5 polymorphisms in KD susceptibility has been
investigated previously. Significant attention has focused on the
widely recognized 32-bp deletion (D32) mutation present in the
coding region of CCR5 that is found mainly in populations of
European ancestry. We reported previously that there was an
inverse relationship between the global distribution of D32 allele
and the incidence of KD [15]. Also, in our large family-based
study in US-trios we had observed an asymmetric transmission of
the CCR5-D32 allele across generations [15]. Further, we had
found that the KD-influencing effects of the CCR5-D32-bearing
HHG*2 haploype were modified by CCL3L1 copy number [15].
Breunis et al [26] replicated our observations in a Northern
European population and observed that the frequency of the
CCR5-D32 allele was lower in cases (6.5%) compared to controls
(10.7%).
The CCR5-D32-bearing HHG*2 haplotype is rarely found in
Asian populations. The results of two prior studies in subjects with
KD of European ancestry [15,26] and a separate study of KD
patients from Korea [19] suggested that other polymorphisms at
the CCR5 locus also associate with susceptibility to KD. However,
in the present study of Japanese subjects, we did not find an
association between CCR5 haplotypes and KD susceptibility. By
contrast, we did find an association of CCR5 haplotypes with KD
outcomes and IVIG-resistance.
Early coronary lesions demonstrate marked infiltration of
neutrophils [45] whereas at later time points show infiltration
predominantly of T-cells and monocytes/macrophages [43].
Members of the chemokine system, including CCR5 and CCL3L1
play an important role in leukocyte trafficking and activation as
well as the pathogenesis of coronary artery diseases such as
arteriosclerosis, hypertension and myocardial infarction [46]. In
our previous study of European-descent KD patients, we found
that the D32-bearing CCR5-HHG*2 haplotype was associated with
not only reduced KD susceptibility, but also a lower risk of CAL
[15]. In the present study, we observed that the CCR5 HHF*2
haplotype which bears the CCR2-64I polyrmorphism is associated
with a reduced the risk of IVIG-resistance and CAL formation.
Whether this association suggests an involvement of CCR2, a
receptor critically involved in monocyte trafficking and activation,
in KD pathogenesis and therapy responses is unclear because the
CCR2-64I polymorphism is in linkage disequilibrium with
promoter polymorphisms in CCR5 [32]. Notwithstanding this
quandary, it is conceivable that the beneficial associations
observed for the CCR2-64I-bearing CCR5 HHF*2 haplotype
with KD-related outcomes may relate either directly or indirectly
to inflammation.
Many demographic and laboratory factors such as patient age,
white blood cell count, and plasma levels of aspartate amino
transferase and C-reactive protein have been identified as risk
factors for IVIG resistance [3,6,8,47,48,49]. Onouchi et al [22]
observed that a functional polymorphism in the ITPKC gene was
associated with response to IVIG in US KD children. The results
of the present study extend the notion that host genetic factors may
influence IVIG resistance. IVIG has been shown to be effective
across a range of autoimmune, inflammatory and infectious
conditions, as well as for post-infectious complications [25]. This
suggests that IVIG may have a broad immunomodulatory
mechanism of action, beyond merely inhibiting antibody-triggered
inflammation. Park-Min et al showed recently that IVIG blocks
cellular activation by interferon-c (IFNc) [50], a proinflammatory
cytokine that plays a key role in cellular immune responses and
Th1-type-driven inflammatory/infectious diseases [51,52]. In this
respect it is notable that CCR5 is expressed on Th1 cells [53], and
thus it is conceivable that polymorphisms in this gene and its
ligands by influencing Th1 pathways may influence IVIG
responses. Because IVIG is far from an optimized therapeutic,
and responses to IVIG vary considerably among patients, future
studies are warranted to identify the broader range of host genetic
Table 3. Association of CCR5 haplotypes and CCL3L1 copy
number with IVIG response.
CCR5 haplotype/CCL3L1
copy number OR 95% CI P value
Full Model
CCR5 HHA 0.83 0.12–5.79 0.851
CCR5 HHC 0.62 0.15–2.52 0.499
CCR5 HHE 0.45 0.13–1.51 0.194
CCR5 HHF*2 0.21 0.54–0.83 0.026
CCL3L1 ,4copies 10.93 1.17–101.99 0.036
CCL3L1 .4 copies 5.12 0.57–46.34 0.146
Final Model (Probability
Criterion of 0.1)
CCL3L1 ,4copies 2.56 0.96–6.87 0.061
CCR5 HHF*2 0.34 0.12–0.95 0.040
Full model shows results from a logistic regression model including all the
indicated predictors while final model indicates the results from the stepwise
regression using a retention criterion of 0.1; OR – Odds Ratio; CI – Confidence
Interval.
doi:10.1371/journal.pone.0011458.t003
CCR2-CCR5-CCL3L1 and KD
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responses.
Although a limitation of our study is the small sample size, our
results are concordant with previous data suggesting a role for
variations in CCL3L1 and CCR5 in KD [15,19,26]. Recent data
suggest that the Japanese population may not be as homogeneous
[54] as once thought and the possibility of population stratification
exists since our controls and cases came from different regions of
Japan. However, despite this limitation it is noteworthy that
similar to the CCR5-D32 polymorphism which has been intensively
scrutinized in persons of European descent, the CCR2-64I
polymorphism has also been associated with variable susceptibility
to multiple diseases as well. Interestingly, while the CCR5-D32
polymorphism is rare among persons of Asian descent, the CCR2-
64I-containing HHF*2 haplotype is very common, and has been
associated with salutary effects (reduced risk) among persons of
Japanese descent for several diseases with immunologic underpin-
nings including multiple sclerosis [55], sarcoidosis [56], and HIV
[57]. Also, it is well-known that CAL is associated with IVIG
resistance [10,47] and concordantly, we found that IVIG-resistant
subjects had a higher proportion of CAL and that the CCR2-64I-
containing HHF*2 haplotype was associated with beneficial effects
for both of these outcomes. Another limitation of our study is that
we had to consider CAL outcomes as a dichotomous variable as
the clinical centers in Japan did not uniformly use Z scores to
characterize the dimension of the lumen of the coronary arteries
[58]. Analyzing these data with arterial internal diameter
normalized for body surface area as a continuous variable may
have yielded more robust results.
Notwithstanding these limitations, our findings underscore that
genetic determinants influence not only inter-individual differenc-
es in KD susceptibility but also inter-subject variation in cardiac
complications and treatment response. In conjunction with
previous studies that have focused on the relationship between
variations in CCR5 and its ligands with KD [15,19,26], the
current findings showing a commonality of the genetic associations
across three different KD-related phenotypes (KD susceptibility,
CAL development and IVIG resistance) together suggest that
CCR5 and its ligands may play an important role in the
pathogenesis of different facets of KD. Of broad importance,
our findings also suggest that host variations may influence
responses to immune modulators such as IVIG.
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